MK-0536 Inhibits HIV-1 Integrases Resistant to Raltegravir

With the U.S. Food and Drug Administration approval of raltegravir (RAL; MK-0518; Merck & Co.), HIV-1 integrase (IN) is the newest therapeutic target for AIDS and HIV infections. Recent structural analyses show that IN strand transfer inhibitors (INSTIs) share a common binding mode in the enzyme...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Métifiot, Mathieu, Johnson, Barry, Smith, Steven, Zhao, Xue Zhi, Marchand, Christophe, Burke, Terrence, Hughes, Stephen, Pommier, Yves
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2011
Matèries:
Antiviral Agents
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3195008/
https://ncbi.nlm.nih.gov/pubmed/21876054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.05288-11
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars